Scarica l'app Stockscreener
82.43
2.95%
2.36
Pre-mercato:
82.42
-0.01
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$80.07
Aprire:
$80.67
Volume 24 ore:
4.17M
Relative Volume:
1.80
Capitalizzazione di mercato:
$15.96B
Reddito:
$8.41B
Utile/perdita netta:
$761.20M
Rapporto P/E:
21.38
EPS:
3.8553
Flusso di cassa netto:
$1.13B
1 W Prestazione:
-10.83%
1M Prestazione:
-8.84%
6M Prestazione:
-18.03%
1 anno Prestazione:
-20.01%
Intervallo 1D:
$80.67
$82.85
Intervallo di 1 settimana:
$79.83
$93.78
Portata 52W:
$79.83
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Nome
Zimmer Biomet Holdings Inc
Settore
Industria
Telefono
(574) 267-6131
Indirizzo
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
82.43 | 16.03B | 8.41B | 761.20M | 1.13B | 3.8553 |
ABT
Abbott Laboratories
|
90.79 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
315.13 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.97 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.61 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.50 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-02-20 | Iniziato | William Blair | Mkt Perform |
| 2026-01-09 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Aggiornamento | Roth Capital | Neutral → Buy |
| 2024-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Iniziato | Wolfe Research | Peer Perform |
| 2024-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-21 | Aggiornamento | Argus | Hold → Buy |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Iniziato | ROTH MKM | Neutral |
| 2023-08-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-05-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-03-29 | Iniziato | UBS | Sell |
| 2023-03-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Underweight |
| 2022-10-12 | Iniziato | Jefferies | Underperform |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-04-01 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Underperform |
| 2022-03-02 | Downgrade | Loop Capital | Buy → Hold |
| 2022-02-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Reiterato | Citigroup | Buy |
| 2022-02-08 | Reiterato | Deutsche Bank | Hold |
| 2022-02-08 | Reiterato | JMP Securities | Mkt Outperform |
| 2022-02-08 | Reiterato | JP Morgan | Neutral |
| 2022-02-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Reiterato | Stifel | Buy |
| 2022-02-08 | Reiterato | Truist | Buy |
| 2022-02-08 | Reiterato | UBS | Neutral |
| 2022-02-08 | Reiterato | Wells Fargo | Underweight |
| 2022-02-02 | Downgrade | UBS | Buy → Neutral |
| 2022-01-19 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Downgrade | Needham | Strong Buy → Buy |
| 2021-12-07 | Iniziato | Loop Capital | Buy |
| 2021-11-23 | Downgrade | Argus | Buy → Hold |
| 2021-09-14 | Ripresa | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-09 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Reiterato | Needham | Strong Buy |
| 2020-10-20 | Iniziato | Northland Capital | Market Perform |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-08-05 | Reiterato | Needham | Strong Buy |
| 2020-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Reiterato | Needham | Strong Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-09-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Aggiornamento | Argus | Hold → Buy |
| 2019-07-30 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Aggiornamento | Needham | Buy → Strong Buy |
Mostra tutto
Zimmer Biomet Holdings Inc Borsa (ZBH) Ultime notizie
Results: Zimmer Biomet Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard holds 7.54% of Zimmer Biomet (ZBH) via Schedule 13G filing - Stock Titan
Zimmer Biomet Stock (US98956P1021): Q3 2025 Earnings Beat Expectations with 5.2% Revenue Growth - AD HOC NEWS
A Look At Zimmer Biomet (ZBH) Valuation After CFO Exit And Solid Quarterly Results - Yahoo Finance
Vanguard Group Inc. Buys 192,517 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet falls after CEO exit, unchanged growth outlook - MSN
Zimmer Biomet Holdings Hits New 52-Week Low at $81.36 - Markets Mojo
Zimmer Biomet Buzz Grows Across NYSE Composite Trend - Kalkine Media
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zimmer Biomet (NYSE:ZBH) Given New $95.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zimmer Biomet Q1 2026 earnings preview - MSN
Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Price Target Cut to $105.00 by Analysts at Citizens Jmp - MarketBeat
Zimmer Biomet CFO Suketu Upadhyay to depart - MSN
Wells Fargo & Company Lowers Zimmer Biomet (NYSE:ZBH) Price Target to $90.00 - MarketBeat
Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $105.00 at Stifel Nicolaus - MarketBeat
Zimmer Biomet's (ZBH) Hold Rating Reaffirmed at Truist Financial - MarketBeat
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2026 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target on Zimmer Biomet Holdings to $95 From $100, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Zimmer Biomet to $95 From $98, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on Zimmer Biomet to $92 From $100, Maintains Neutral Rating - marketscreener.com
Zimmer Biomet net sales up 9.3% to USD 2.087B in Q1 2026 - Medical Buyer
Barclays Adjusts Price Target on Zimmer Biomet to $94 From $100, Maintains Underweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Zimmer Biomet to $86 From $89, Maintains Sell Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Zimmer Biomet to $90 From $98, Maintains Equalweight Rating - marketscreener.com
Stifel Adjusts Price Target on Zimmer Biomet to $105 From $110, Maintains Buy Rating - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Hits New 12-Month LowShould You Sell? - MarketBeat
Citizens cuts Zimmer Biomet stock price target on mixed results By Investing.com - Investing.com Canada
Citizens cuts Zimmer Biomet stock price target on mixed results - Investing.com
Cwm LLC Reduces Stock Position in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings Inc (ZBH) Q1 2026 Earnings Call Highlights: Strong Start with 9.3% Revenue Growth - GuruFocus
Zimmer Biomet Q1 Earnings Call Highlights - Yahoo Finance
Zimmer Biomet (ZBH) Proxy filing Summary - Quartr
Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Yahoo Finance
Stifel cuts Zimmer Biomet stock price target on mixed quarter By Investing.com - Investing.com India
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MSN
A Look at Zimmer Biomet Holdings Inc (ZBH) After 10.6% Decline -- GF Value $127.12 vs Price $82.80 - GuruFocus
Zimmer Biomet Faces Management and Operational Changes, but Wide Moat Remains Constant - Morningstar
Analyst Maintains Buy on Zimmer Biomet, Keeps $109 Price Target Amid Ongoing Multi-Year Transformation - TipRanks
Truist cuts Zimmer Biomet stock price target on execution risks - Investing.com
Stifel cuts Zimmer Biomet stock price target on mixed quarter - Investing.com
Truist cuts Zimmer Biomet stock price target on execution risks By Investing.com - Investing.com Canada
Zimmer Biomet Holdings reports a 31% increase in first-quarter earnings - The Journal Gazette
Zimmer Biomet (NYSE:ZBH) Shares Down 8.8%Should You Sell? - MarketBeat
Tariffs Benefit, CFO Exit: What's Going On With Zimmer Biomet Stock On Tuesday? - Benzinga
Zimmer Biomet Announces Chief Financial Officer Transition - GuruFocus
Zimmer Biomet (ZBH) Faces Decline Amid CFO Departure and Strong Q1 Earnings - GuruFocus
Zimmer Biomet Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Zimmer Biomet Stock Sank After a Q1 Earnings Beat and Raised Profit Outlook - TechStock²
Zimmer Biomet stock hits 52-week low at $84.56 By Investing.com - Investing.com Canada
Zimmer Biomet Holdings Inc Azioni (ZBH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):